(±) -NBI-74330

(±) -NBI-74330 is a potent and selective CXCR3 antagonist. (±) -NBI-74330 not only reduces tactile and thermal hypersensitivity but also enhances the analgesic properties of morphine. (±) -NBI-74330 can reduce microglial cell activation, increase astroglial cell activation, and downregulate the expression of some CXCR3 ligands in a rat neuropathic pain model[1].

Product Specifications

CAS Number

[473722-68-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/racemic-nbi-74330.html

Purity

99.12

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C2=C(N=C(C(C)N(CC3=CC=CN=C3)C(CC4=CC=C(C(C(F)(F)F)=C4)F)=O)N1C5=CC=C(C=C5)OCC)N=CC=C2

Molecular Formula

C32H27F4N5O3

Molecular Weight

605.58

Precautions

H302, H315, H319, H335

References & Citations

[1]Piotrowska A, et al. Pharmacological blockade of CXCR3 by (±) -NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies. Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864 (10) :3418-3437.